Olive Extract for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

Olive Extract for Health & Longevity

Created on 08/25/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

A concentrated preparation of olive leaves or fruit. The strongest and most consistent finding is a reduction in blood pressure, clearest at the higher of the two doses commonly sold and in people whose pressure is already elevated. Effects on cholesterol and blood sugar are genuinely conflicted. The main hazards follow from the main benefit. Product strength varies enormously. (Full Review)

Protocol

Standard leaf extract protocol
500–1,000 mg daily
Olive leaf extract standardized to 16–20% oleuropein, supplying roughly 100–136 mg oleuropein
Best time of day
With morning and evening meals
No circadian advantage is established; dosing with food is chosen for tolerability
Single versus split dosing
Split dosing preferred
Preferred on pharmacokinetic grounds given the short half-life; the two were never compared directly
Time to effect
Blood pressure
4–8 weeks
Changes appear at 4–8 weeks and plateau by 12
Lipids and glucose
6–12 weeks
Applies only where lipid and glucose changes occur at all
Bone markers
12 months
Bone marker changes required 12 months

Benefits

Contraindications
  • Pregnancy and lactation
  • Documented olive fruit or Oleaceae pollen allergy, including olive pollen-food syndrome
  • Symptomatic orthostatic hypotension, or resting systolic blood pressure below 100 mmHg
  • Recurrent hypoglycemia on insulin or sulfonylurea therapy (glucose below 70 mg/dL more than twice weekly)
  • Severe hepatic impairment (Child-Pugh Class C)
  • Untreated hyperthyroidism, or thyroid-stimulating hormone suppressed below 0.1 mIU/L
  • Scheduled surgery within 14 days
    •
Key Interactions
  • Antihypertensive drugs: ACE inhibitors (lisinopril, ramipril), angiotensin receptor blockers (losartan, valsartan), calcium channel blockers (amlodipine), diuretics
  • Insulin and insulin-releasing drugs: insulin, sulfonylureas (glipizide, glyburide)
  • Levothyroxine and antithyroid drugs
  • Over-the-counter medications: nonsteroidal anti-inflammatory drugs (ibuprofen, naproxen), oral decongestants (pseudoephedrine, phenylephrine)
  • Blood-pressure-lowering supplements: beetroot nitrate, hibiscus, garlic extract, magnesium, potassium, coenzyme Q10
  • Glucose-lowering supplements: berberine, cinnamon extract, chromium picolinate, alpha-lipoic acid
  • Other interventions: prolonged fasting, ketogenic or very-low-carbohydrate protocols, high-volume endurance training
    •

Risk & Side Effects

  • High: Excessive Blood Pressure Reduction in Treated Hypertension
    •
  • Medium: Gastrointestinal Discomfort; Additive Glucose Lowering with Antidiabetic Therapy
    •
  • Low: Allergic Reactions in Olive-Sensitized Individuals; Thyroid Hormone Stimulation
    •
  • Speculative: Hepatic Strain in Pre-existing Liver Impairment; Increased Bleeding Tendency with Antiplatelet Therapy
    •

Monitoring

Marker Target Why
Systolic / diastolic blood pressure 110–120 / 70–80 mmHg Primary target and primary risk marker
Fasting glucose 75–86 mg/dL Detects both benefit and additive hypoglycemia
Hemoglobin A1c (HbA1c) 4.8–5.4% Three-month average glucose exposure
Fasting insulin 2–5 µIU/mL Tracks the insulin sensitivity endpoint that improved in trials
Triglycerides Below 80 mg/dL The lipid fraction that moved most consistently
Low-density lipoprotein cholesterol (LDL-C) Below 100 mg/dL, or individualized to overall risk The lipid fraction olive polyphenols protect from oxidation
High-sensitivity C-reactive protein (hs-CRP) Below 0.5 mg/L Inflammation endpoint reported in the largest trial
Alanine aminotransferase (ALT) 10–26 U/L Screens the theoretical hepatic concern
Thyroid-stimulating hormone (TSH) 0.5–2.0 mIU/L Detects the thyroid stimulation seen in animal studies

Cadence: Home blood pressure twice daily for four weeks, then weekly; fasting glucose daily for four weeks in anyone on insulin or a sulfonylurea; a full repeat blood panel at 12 weeks; thyroid-stimulating hormone at 8–12 weeks; and thereafter a repeat panel every 6–12 months.

Qualitative Assessment

  • Lightheadedness on standing, which is the earliest sign of excessive blood pressure reduction
  • Shakiness, sweating or confusion before meals, indicating additive glucose lowering
  • Stomach pain, nausea or loose stools, the most common tolerability complaint
  • Number of sick days per respiratory illness episode, compared with prior seasons
  • Palpitations, heat intolerance or unexplained weight loss, which would suggest thyroid over-stimulation
  • Perceived exercise recovery and session quality, tracked as a simple daily rating
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.